News Releases Year: - Any -2021202020192018201720162015201420132012 Items per page 102550 02/16/21 Summary ToggleClearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program PDF Version 02/08/21 Summary ToggleClearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting PDF Version 01/12/21 Summary ToggleClearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD PDF Version 01/06/21 Summary ToggleClearside Biomedical Announces Pricing of $12 Million Registered Direct Offering PDF Version 11/16/20 Summary ToggleClearside Biomedical Announces Data Presentations at the American Academy Ophthalmology (AAO) 2020 Annual Meeting and Publication on the Suprachoroidal Injection Procedure in Translational Vision Science and Technology PDF Version 11/11/20 Summary ToggleClearside Biomedical to Present at the Stifel 2020 Virtual Healthcare Conference PDF Version 11/10/20 Summary ToggleClearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update PDF Version 10/30/20 Summary ToggleClearside Biomedical to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Tuesday, November 10, 2020 PDF Version 09/23/20 Summary ToggleClearside Biomedical Announces Clinical Data Presentations at The Retina Society 2020 and Publication of XIPERE™ Data in Diabetic Macular Edema in Ophthalmology Retina PDF Version 09/11/20 Summary ToggleClearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery PDF Version Pagination First page First Previous page Page 2 Current page 3 Page 4 Page 5 Next page Last page Last
